Pulse Biosciences (PLSE)

Company Profile

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first commercial product to harness the distinctive advantages of the Company's proprietary Nano-Pulse Stimulation™ (NPS™) technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue, to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model.

Company profile

Ticker

PLSE

Exchange

NASDAQ

Website

www.pulsebiosciences.com

CEO

Darrin R. Uecker

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Surgical and Medical Instrument Manufacturing

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • West Pharmaceutical Services • Haemonetics • Hill-Rom ...

Former names

Electroblate, Inc.

SEC CIK

0001625101

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

NanoBlate Corp. • BioElectroMed Corp. • Pulse Biosciences BV • 2783162 Ontario Inc. ...

PLSE stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

Conflict minerals disclosure

31 May 23

8-K

Departure of Directors or Certain Officers

11 May 23

Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results

11 May 23

S-8

Registration of securities for employees

10 May 23

8-K

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

10 May 23

8-K

Entry into a Material Definitive Agreement

9 May 23

8-K

Departure of Directors or Certain Officers

5 May 23

8-K

Pulse Biosciences Announces $65 Million Private Placement

1 May 23

DEFA14A

Additional proxy soliciting materials

14 Apr 23

Transcripts

View all

PLSE

Earnings call transcript

2023 Q1

11 May 23

PLSE

Earnings call transcript

2022 Q4

30 Mar 23

PLSE

Earnings call transcript

2022 Q3

11 Nov 22

PLSE

Earnings call transcript

2022 Q2

10 Aug 22

PLSE

Earnings call transcript

2022 Q1

12 May 22

PLSE

Earnings call transcript

2021 Q4

1 Apr 22

PLSE

Earnings call transcript

2021 Q3

16 Nov 21

PLSE

Earnings call transcript

2021 Q2

10 Aug 21

PLSE

Earnings call transcript

2021 Q1

11 May 21

PLSE

Earnings call transcript

2020 Q4

23 Feb 21

Latest ownership filings

View all

Financial summary

Financial statements Chart PLSE financial data

Quarter (USD)	Mar 23	Dec 22	Sep 22	Jun 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	54.10 mm	54.10 mm	54.10 mm	54.10 mm	54.10 mm	54.10 mm
Cash burn (monthly)	2.35 mm	(no burn)	3.27 mm	4.22 mm	2.19 mm	3.17 mm
Cash used (since last report)	5.19 mm	n/a	7.23 mm	9.32 mm	4.84 mm	7.00 mm
Cash remaining	48.91 mm	n/a	46.87 mm	44.77 mm	49.25 mm	47.10 mm
Runway (months of cash)	20.8	n/a	14.3	10.6	22.5	14.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

PLSE institutional ownership history Ownership history

7.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	30	34	-11.8%
Opened positions	5	5	–
Closed positions	9	17	-47.1%
Increased positions	8	6	+33.3%
Reduced positions	6	12	-50.0%

13F shares	Current	Prev Q	Change
Total value	5.89 bn	8.50 mm	+69182.7%
Total shares	2.95 mm	2.88 mm	+2.3%
Total puts	131.70 k	0.00	NEW
Total calls	337.20 k	458.80 k	-26.5%
Total put/call ratio	0.4	–	–

Largest owners	Shares	Value	Change
BAC Bank Of America	768.74 k	$2.13 bn	-0.1%
Vanguard	564.77 k	$1.56 bn	+0.1%
Duggan Robert W	492.07 k	$1.27 mm	0.0%
BLK Blackrock	223.70 k	$619.65 mm	+0.3%
Griffin Asset Management	175.89 k	$487.22 mm	+104.9%
Geode Capital Management	139.56 k	$386.00 k	+4.8%
Westside Investment Management	138.61 k	$383.00 k	-4.2%
NTRS Northern Trust	73.78 k	$204.37 mm	-0.5%
STT State Street	68.10 k	$188.64 mm	NEW
Advisor	67.31 k	$186.70 mm	+36.7%

Largest transactions	Shares	Bought/sold	Change
Griffin Asset Management	175.89 k	+90.06 k	+104.9%
STT State Street	68.10 k	+68.10 k	NEW
Spotlight Asset	0.00	-66.43 k	EXIT
Ergoteles	0.00	-37.10 k	EXIT
State Of Wisconsin Investment Board	39.30 k	-25.10 k	-39.0%
Citadel Advisors	24.57 k	+24.57 k	NEW
WealthTrust Axiom	21.50 k	+21.50 k	NEW
Advisor	67.31 k	+18.08 k	+36.7%
Susquehanna International	13.65 k	+13.65 k	NEW
Millennium Management	45.05 k	-13.61 k	-23.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PLSE insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
9 May 23	Duggan Robert W	Common Stock	Buy	Acquire P	No	No	6.51	10,022,937	65.25 mm	30,414,661
8 May 23	Levinson Mitchell E.	Stock Option Common Stock	Grant	Acquire A	No	No	8.02	17,700	141.95 k	17,700
29 Apr 23	Kevin Patrick Danahy	Stock Option Common Stock	Grant	Acquire A	No	No	6.44	500,000	3.22 mm	500,000
29 Apr 23	Uecker Darrin	Stock Option Common Stock	Grant	Acquire A	No	No	6.44	500,000	3.22 mm	500,000
17 Apr 23	Levinson Mitchell E.	Stock Option Common Stock	Grant	Acquire A	No	No	5.81	2,000	11.62 k	2,000
7 Oct 22	Levinson Mitchell E.	Common Stock	Buy	Acquire P	Yes	No	2.29	4,300	9.85 k	5,034
7 Oct 22	Levinson Mitchell E.	Common Stock	Buy	Acquire P	Yes	No	2.23	4,500	10.04 k	5,234
7 Oct 22	Levinson Mitchell E.	Common Stock	Buy	Acquire P	Yes	No	2.26	4,400	9.94 k	5,134
7 Oct 22	Levinson Mitchell E.	Common Stock	Buy	Acquire P	Yes	No	2.27	8,810	20.00 k	12,945
7 Oct 22	Levinson Mitchell E.	Common Stock	Buy	Acquire P	No	No	2.29	8,770	20.08 k	46,274